asthma
A total of 642 patients with chronic asthma       (FEV(1) 50 to 85% of predicted value and at least a predefined level of asthma       symptoms) incompletely controlled with inhaled beclomethasone, 200 microg twice       daily using a spacer device, during the 4-wk run-in period were randomly       allocated, in a double-blind, double-dummy manner to one of four treatment       groups: (1) montelukast 10 mg plus continuing inhaled beclomethasone; (2) placebo       tablet plus continuing inhaled beclomethasone; (3) montelukast 10 mg and inhaled        placebo (after blind beclomethasone removal); and (4) placebo tablet and inhaled        placebo (after blind beclomethasone removal).
A total of 642  @OBJECT$   @PREDICAT$  chronic  @SUBJECT$        (FEV(1) 50 to 85% of predicted value and at least a predefined level of asthma       symptoms) incompletely controlled with inhaled beclomethasone, 200 microg twice       daily using a spacer device, during the 4-wk run-in period were randomly       allocated, in a double-blind, double-dummy manner to one of four treatment       groups: (1) montelukast 10 mg plus continuing inhaled beclomethasone; (2) placebo       tablet plus continuing inhaled beclomethasone; (3) montelukast 10 mg and inhaled        placebo (after blind beclomethasone removal); and (4) placebo tablet and inhaled        placebo (after blind beclomethasone removal).